Evidence map›Paper›PMID 34671120›Full record

ArticleBone marrow transplantation2022

Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.

Feng-Ming Tien, Xavier Cheng-Hong Tsai, Sheng-Chuan Huang, Jia-Hau Liu, Chien-Yuan Chen, Yuan-Yeh Kuo, Yi-Kuang Chuang, Mei-Hsuan Tseng, Yen-Ling Peng, Ming-Chih Liu and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Blood science (Baltimore, Md.) · 2025
    Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation.Blood and lymphatic cancer : targets and therapy · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Feng-Ming TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-4513-2472
Xavier Cheng-Hong TsaiDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-4174-8766
Sheng-Chuan HuangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Jia-Hau LiuDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chien-Yuan ChenDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yuan-Yeh KuoTai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Yi-Kuang ChuangTai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Mei-Hsuan TsengDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yen-Ling PengDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Ming-Chih LiuDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Wen LiuDepartment of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Xiu-Wen LiaoTai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Liang-In LinDepartment of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Yu-Sin WuDepartment of Nursing, National Taiwan University Cancer Center, Taipei, Taiwan.
Mei-Fang HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shang-Ju WuDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Szu-Chun HsuDepartment of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Bor-Sheng KoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Wen-Chien ChouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-2967-698X
Ming YaoDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Hsin-An HouDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hsinanhou@ntu.edu.tw.
Jih-Luh TangDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. tangntuh@gmail.com.ORCID 0000-0003-4021-3281
Hwei-Fang TienDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-1384-5593
National Taiwan University Hospital · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mutant burden of FLT3-ITD modulates its prognostic impact on patients with acute myeloid leukemia (AML). However, for patients with low allelic ratio (AR) FLT3-ITD (FLT3-ITD

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3HumansMutationNucleophosminPrognosisRemission InductionFLT3 protein, humanfms-Like Tyrosine Kinase 3Nucleophosmin

Identifiers

PMID34671120
OpenAlexW3205202937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.